Drug Database
AM

amphotericin B (Ampholip)

✓ Approved

Bharat Serums and Vaccines Limited · Small Molecule · Small Molecule

What is amphotericin B?

amphotericin B is a small molecule developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAmpholip
CompanyBharat Serums and Vaccines Limited
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Bharat Serums and Vaccines Limited

Therapeutic Indications

amphotericin B is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Cardiac disordersEndocardial disease✓ Approved
Infections and infestationsCandida infection✓ Approved
Infections and infestationsAspergillus infection✓ Approved

Related Research Articles

PubMedTherapeutic advances in infectious disease2026-07-25

Magnusiomyces clavatus fungemia treated with combination antifungals including isavuconazole in an immunocompromised pediatric patient: a case report.

McPherson Amanda Z AZ, Miller Matthew M, Rytlewski Kacie K, Bacon Samantha S et al.

Magnusiomyces clavatus, formerly Saprochaete clavata or Geotrichum clavatum, is an ascomycetous yeast found in the environment as well as the gastrointestinal and respiratory tracts of humans. It has been described as an emerging, albeit rare, cause of invasive fungal disease affecting immunocompromised patients. Intrinsic resistance to fluconazole and echinocandins has been theorized; however, little else is known regarding optimal treatment regimens for this opportunistic pathogen. To our knowledge, only 13 infectious cases have been described in pediatric patients, all of which utilized a combination of antifungals including liposomal amphotericin B (LAmB) and voriconazole with or without flucytosine (5-FC). Here we report a case of a 4-year-old, 12.3 kg, female patient who immigrated from Ukraine and was admitted to our institution for an allogeneic umbilical cord blood transplant in the setting of bone marrow failure secondary to Fanconi anemia. On day +6 after cell transplantation, the patient developed febrile neutropenia found to be because of invasive M. clavatus fungemia on day +7. The patient was empirically treated with LAmB, micafungin, and posaconazole (POS), the latter of which failed to reach therapeutic levels. Ultimately, our patient defervesced and cleared blood cultures after transitioning LAmB to 5-FC, followed by definitive treatment with isavuconazole (ISA) monotherapy. To our knowledge, this is the first case of pediatric M. clavatus ultimately treated with 5-FC plus POS followed by ISA alone.

PMID 42499393
Read full article →
PubMedFrontiers in cellular and infection microbiology2026-07-25

Candida auris: a review of global epidemiology, multidrug resistance, and infection control in healthcare-associated outbreaks.

Du Xuewei X, Li Li L

Candida auris, designated a critical-priority fungal pathogen by the World Health Organization, poses a growing threat to healthcare systems worldwide. Analysis of 80 peer-reviewed studies reveals five principal findings: (1) C. auris exhibits clade-dependent geographic distribution and resistance profiles-Clade I (South Asia) and Clade III show fluconazole resistance exceeding 90%, whereas Clade IV exhibits 44% resistance; echinocandin resistance varies significantly by clade and no resistance was detected in certain clades; amphotericin B resistance varies from no detected resistance to 46% depending on clade; and pan-resistant strains have emerged; (2) biofilm-associated C. auris cells (sessile cells) exhibit MBECs 2- to 4,119-fold higher than planktonic MICs, representing a major driver of persistent colonization; (3) novel antifungal agents, including ibrexafungerp, manogepix (the active moiety of fosmanogepix), and rezafungin, demonstrate promising in vitro activity against C. auris, with manogepix showing the highest overall antibiofilm activity (geometric mean MBEC of 5.9 μg/mL) and ibrexafungerp demonstrating superior activity against Clade IV biofilms; (4) a tiered infection prevention and control (IPC) framework-integrating universal screening, contact precautions, and environmental decontamination-has been associated with reduced transmission rates in outbreak settings; and (5) climate change and global warming may have contributed to the emergence of C. auris through thermal adaptation of environmental fungal species. These findings indicate that effective mitigation of the C. auris threat requires integrated surveillance, susceptibility-guided therapy accounting for both planktonic and biofilm activity, and resilient healthcare systems adapted to the clade-specific epidemiology of this pathogen.

PMID 42499548
Read full article →
PubMedFrontiers in oncology2026-07-25

Concurrent B-cell acute lymphoblastic leukemia and plasma cell neoplasm with plasmablastic features supporting divergent evolution from a shared precursor: a case report.

Babić Antonija A, Franić Šimić Ivana I, Knežević Josip J, Gjadrov Kuveždić Koraljka K et al.

B-cell malignancies comprise a biologically diverse group of neoplasms, with only rare reports describing the co-occurrence of two distinct lymphoid entities. While concurrent presentation of mature B-cell neoplasms has been documented, the simultaneous occurrence of B-cell acute lymphoblastic leukemia (B-ALL) and plasma cell neoplasm (PCN) has previously been reported rarely. Such cases may provide insight into the clonal architecture and evolutionary pathways underlying lymphoid malignancies. We report a 76-year-old man presenting with cytopenias and leukocytosis, in whom initial bone marrow evaluation and immunophenotyping established a diagnosis of B-ALL with a pre-B phenotype. At the time of diagnosis, flow cytometry also identified a distinct population of aberrant plasma cells, raising the possibility of a concurrent plasma cell neoplasm. Follow-up bone marrow analysis confirmed the coexistence of two immunophenotypically and morphologically distinct malignant populations: immature lymphoblasts consistent with B-ALL and clonal plasma cells. Initial ALL-directed therapy induced remission of both components. However, subsequent disease evolution demonstrated a clear phenotypic shift, with relapse characterized by expansion of a plasmablastic/plasma cell population consistent with PCN, while the B-ALL component remained undetectable by minimal residual disease assessment. Treatment was therefore redirected toward a myeloma-based regimen, which was limited by toxicity and failed to achieve disease control. Genomic analysis supported the presence of two clonally related but distinct malignancies. These findings support a model of early clonal divergence from a common progenitor rather than independent malignancies or linear differentiation. This case highlights the complexity of clonal evolution in B-cell malignancies and underscores the importance of integrated genomic and immunophenotypic analysis in understanding disease biology.

PMID 42500292
Read full article →
PubMedJournal of the American Pharmacists Association : JAPhA2026-07-25

Community pharmacists' perceptions of long-acting injectable buprenorphine administration in community pharmacies: A cross-sectional survey study.

Marley Grace G, Farrel Brianna B, Carpenter Delesha D

Long-acting injectable buprenorphine (LAI-B) is an evidence-based medication for opioid use disorder (MOUD), but its implementation in community pharmacies has not been well studied. This study's objective was to assess southeastern North Carolina (NC) community pharmacist perspectives on the perceived acceptability, appropriateness, and feasibility of LAI-B administration and identify the barriers and facilitators to LAI-B administration in community pharmacies. We conducted an online survey of practicing community pharmacists between January 14 and March 14, 2026. The survey assessed knowledge of and willingness to administer LAI-B, perceived benefits and barriers, training needs, and perceived acceptability, appropriateness, and feasibility of administering LAI-B. Descriptive statistics are reported. Forty-four eligible responses were included in the analysis (response rate= 16%). On average, pharmacists were neutral to somewhat willing to administer LAI-B and also had neutral-to-positive perceptions of acceptability, appropriateness, and feasibility. The most frequently endorsed benefits of LAI-B were decreased diversion, supporting patients in recovery, reducing overdose deaths, and increasing revenue. The most prominent barriers involved reimbursement and payment. Other barriers included limited training, workflow constraints, and lack of provider referrals. Pharmacists reported low knowledge regarding LAI-B Risk Evaluation and Mitigation Strategy requirements, follow-up monitoring, and storage, and expressed interest in training on those topics. Pharmacy-based LAI-B administration could be a promising strategy to expand access to MOUD. However, implementation will require clearer reimbursement pathways, targeted training, and workflow support.

PMID 42498130
Read full article →
PubMedJournal of environmental sciences (China)2026-07-25

Bloom of Blixaea quinquecornis (Abé) Gottschling (Dinophyceae) with Chaetoceros tenuissimus Meunier in the South Atlantic: Morphology, molecular characterization, and toxins.

Guennes Marcella M, Goulart Amanda Santos AS, Salgueiro Fabiano F, Lange Priscila Kienteca PK et al.

Blixaea quinquecornis (Abé) Gottschling is a monotypic and cosmopolitan marine dinoflagellate with a Chaetoceros derived tertiary plastid (a dinotom). An extensive bloom of B. quinquecornis that covered 80 km² and extended to 15 km away from the coastline occurred at the Brazilian Northeast coast. B. quinquecornis abundances of 2.3 × 10⁶ cells/L were recorded, causing water discoloration. Molecular analysis of field cells confirmed the identity of B. quinquecornis and the diatom Chaetoceros tenuissimus Meunier, that was found in close association with the dinoflagellate. B. quinquecornis presented the typical morphology of the species, with a conical epitheca, and hypotheca with four antapical spines. Mean cell length was 23.3 ± 2.8 µm and width 19.5 ± 2.8 µm. Toxin screening (PSTs, palytoxins, brevetoxins) showed negative results, though the presence of a putative new palytoxin analogue cannot be excluded. This study presented the first comprehensive characterization of B. quinquecornis, combining morphological description, molecular phylogeny and toxin screening, and contributed with the second molecular sequence of this species. It is noteworthy that B. quinquecornis was found in close association with Chaetoceros tenuissimus, the original diatom-derived tertiary plastid in B. quinquecornis. Future research should prioritize establishing cultures of B. quinquecornis to definitively resolve the nature of its plastid association (kleptoplastidy vs. permanent endosymbiosis) and to enable more comprehensive toxin biosynthesis investigations.

PMID 42498397
Read full article →
PubMedTrends in genetics : TIG2026-07-25

B chromosomes put the 'super' in supernumerary.

Samuelson Kaylah B KB, Hanlon Stacey L SL

In addition to the essential set of chromosomes, individuals can carry supernumerary chromosomes that are not required for normal growth, development, or reproduction. Collectively, these extra chromosomes are called B chromosomes, and modern advances in genomic and cytological technology have accelerated our understanding of their fascinating biology. Here, we provide a brief history of B chromosome research, followed by an examination of their formation and dynamics. We conclude with an outlook on what the novel biology of B chromosomes can teach us and how it can be exploited as important tools for biotechnology, agriculture, and the advancement of human health.

PMID 42498533
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about amphotericin B